Oct 27,2022

Dexcom Reports Third Quarter 2022 Financial Results

DexCom today reported its financial results as of and for the quarter ended September 30, 2022. In the third quarter of 2022, worldwide revenue grew 18% to $769.6 million, up from $650.2 million in the third quarter of 2021. Volume growth in conjunction with strong new customer additions continues to be the primary driver of revenue growth as awareness of real-time CGM increases.

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 27,2022

Better Therapeutics names new chief commercial officer

Better Therapeutics announced today that it appointed Diane Gomez-Thinnes as its new chief commercial officer (CCO). Gomez-Thinnes’ appointment became effective yesterday, Oct. 26, 2022. She joins the San Francisco-based company, which develops prescription digital therapeutics (PDTs). They use a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, including diabetes.

View Analyst & Ambassador Comments
Go to original news
Oct 28,2022

Abbott FreeStyle Libre named ‘best medical technology’ in last 50 years by Galien Foundation

Abbott announced today that the Galien Foundation picked its FreeStyle Libre continuous glucose monitor (CGM) for a major award. The foundation named FreeStyle Libre as the best “Best Medical Technology” of the last 50 years. Other medtech receiving the designation included Edwards Lifesciences’ Sapien 3 Ultra TAVR and Roche’s Cobas HPV test.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 31,2022

New Technology Area on the DigiBete App

DigiBete has recently added a new technology area on the wheel of its app. In this new section users can hear about all the latest technology available to help manage type 1 diabetes. They have also added the ability to choose your preferred language for all the essential films.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 04,2019

WaveForm Technologies and A. Menarini Diagnostics S.r.l. Enter Commercial Agreement for International Distribution of CGM Solutions

WaveForm Technologies Inc. a wholly owned subsidiary of WaveForm Diabetes (formerly AgaMatrix Holdings, LLC) and developer of novel products for continuous glucose monitoring, and A. Menarini Diagnostics S.r.l., a leading diagnostics company, today announced a partnership to commercialize the WaveForm Technologies Continuous Glucose Monitor (CGM). The innovative WaveForm CGM was specifically chosen to integrate within A. Menarini Diagnostics’ connected diabetes care platform. According to the agreement, A. Menarini Diagnostics will perform sales, marketing, training, and customer support for the WaveForm CGM in a long term partnership in territories throughout EMEA and LATAM.

COLLABORATION PARTNERSHIP

#product & service

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 05,2019

WaveForm Technologies Inc Awarded CE Mark Approval for Their CGM System

WaveForm Technologies Inc. a wholly owned subsidiary of AgaMatrix Holdings, LLC and developer of novel continuous glucose monitoring products, today announced it has received CE Mark approval for its Cascade Continuous Glucose Monitoring (CGM) system. Commercialization of the product for the European market is anticipated to begin in select countries.

REGULATORY CE MARK

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 09,2018

AgaMatrix Enters Strategic Partnership with Arcadia Group for Choice Brand Diabetes Monitoring Devices

AgaMatrix and Arcadia Group announced today a strategic partnership leveraging AgaMatrix’s proprietary blood glucose monitoring (BGM) technology for the Choice line of diabetes products marketed by Arcadia. AgaMatrix and Arcadia Group announced today a strategic partnership leveraging AgaMatrix’s proprietary blood glucose monitoring (BGM) technology for the Choice line of diabetes products marketed by Arcadia.

COLLABORATION PARTNERSHIP

#connected device

#bgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 07,2017

AgaMatrix and Glytec Announce Strategic Partnership

AgaMatrix, Inc. and Glytec announced today they are partnering to optimize clinical access to accurate glucose data and insulin titration support through a cloud-based diabetes management platform. AgaMatrix is integrating their FDA-cleared Jazz Wireless 2 Bluetooth® Blood Glucose Monitoring System with Glytec’s eGlycemic Management System® (eGMS®), featuring FDA-cleared Glucommander™ for evidence-based insulin dosing decision support.

COLLABORATION PARTNERSHIP

#connected device

#bgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 02,2019

AgaMatrix, Inc. and WaveForm Technologies, Inc. Complete $56 Million Capital Raise

AgaMatrix, Inc. (“AgaMatrix”) and WaveForm Technologies, Inc. (“WaveForm”), wholly owned subsidiaries of WaveForm Diabetes (formerly AgaMatrix Holdings, LLC), today announced that it closed on a total capital raise of $56 million. The raise includes over $6 million in financing from existing and new investors and $50 million in senior financing from Perceptive Advisors. The proceeds from the capital raise will be used for repayment of debt and to support increased production capacity, product development, and additional clinical trial initiatives for the commercialization of WaveForm’s Continuous Glucose Monitor (CGM) in Europe and FDA clearance in the USA.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Jun 20,2018

AgaMatrix Partners With College Diabetes Network

AgaMatrix is joining with the College Diabetes Network (CDN) as a corporate partner to support their work with young adults across college campuses nationwide, and to introduce them to our innovative connected monitoring solutions.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES